184 related articles for article (PubMed ID: 14510087)
1. Treatment of patients with haemophilia and inhibitory antibodies.
Giangrande PL
Indian J Pediatr; 2003 Aug; 70(8):655-9. PubMed ID: 14510087
[TBL] [Abstract][Full Text] [Related]
2. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Matino D; Makris M; Dwan K; D'Amico R; Iorio A
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004449. PubMed ID: 26677005
[TBL] [Abstract][Full Text] [Related]
4. Ten-year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan.
Takedani H; Shima M; Horikoshi Y; Koyama T; Fukutake K; Kuwahara M; Ishiguro N
Haemophilia; 2015 May; 21(3):374-379. PubMed ID: 25521821
[TBL] [Abstract][Full Text] [Related]
5. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
Pinto P; Ghosh K; Shetty S
Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis in haemophilia with inhibitors: update from international experience.
Carcao M; Lambert T
Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334
[TBL] [Abstract][Full Text] [Related]
7. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
Villarrubia R; Oyagüez I; Álvarez-Román MT; Mingot-Castellano ME; Parra R; Casado MA
Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
[TBL] [Abstract][Full Text] [Related]
8. Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization.
Kruse-Jarres R
Haemophilia; 2014 Sep; 20 Suppl 6():1. PubMed ID: 24975699
[No Abstract] [Full Text] [Related]
9. Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.
Tellier Z; André MH; Polack B
Clin Rev Allergy Immunol; 2009 Oct; 37(2):125-34. PubMed ID: 19184560
[TBL] [Abstract][Full Text] [Related]
10. Management of factor VIII inhibitors: evolution and current status.
Bloom AL
Haemostasis; 1992; 22(5):268-75. PubMed ID: 1478538
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors in haemophilia: clinical aspects.
Dimichele D; Rivard G; Hay C; Antunes S
Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
[TBL] [Abstract][Full Text] [Related]
12. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
13. The use of agents that by-pass factor VIII inhibitors in patients with haemophilia.
Roberts HR
Vox Sang; 1999; 77 Suppl 1():38-41. PubMed ID: 10529686
[No Abstract] [Full Text] [Related]
14. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
[TBL] [Abstract][Full Text] [Related]
15. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
16. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
17. Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand.
Lloyd JV; Street AM; Berry E; McPherson J; Ekert H; Lammi A; McWhirter WR; Duncan EM; Maxwell EL; Rowell J; Baker RI; Leahy MF; Jupe D
Aust N Z J Med; 1997 Dec; 27(6):658-64. PubMed ID: 9483232
[TBL] [Abstract][Full Text] [Related]
18. Summary report of the First International Conference on inhibitors in haemophilia A.
Lacroix-Desmazes S; Scott DW; Goudemand J; Van Den Berg M; Makris M; Van Velzen AS; Santagostino E; Lillicrap D; Rosendaal FR; Hilger A; Sauna ZE; Oldenburg J; Mantovani L; Mancuso ME; Kessler C; Hay CRM; Knoebl P; Di Minno G; Hoots K; Bok A; Brooker M; Buoso E; Mannucci PM; Peyvandi F
Blood Transfus; 2017 Oct; 15(6):568-576. PubMed ID: 27893354
[No Abstract] [Full Text] [Related]
19. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
[No Abstract] [Full Text] [Related]
20. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
[Next] [New Search]
